Tirzepatid 30 mg

▎ Ọdịdị Tirzepatid

▎ Nyocha Tirzepatid

Gịnị bụ ndabere nyocha nke Tirzepatid?

Nchọpụta nyocha nke Tirzepatid sitere na nyocha nke ọgwụ ọgwụgwọ ọrịa shuga yana ọchịchọ maka ọgwụ nchịkwa ibu. Ọgwụ ọgwụgwọ ọrịa shuga ọdịnala nwere oke, ebe GLP-1 agonists ndị na-anabata ya na-egosipụta nrụpụta dị ukwuu n'ịkwalite njikwa glucose ọbara, na-akpali ndị nyocha imepụta ọgwụ dị irè nke otu klas ahụ. Dị ka onye na-anabata GIP/GLP-1 dual agonist, Tirzepatid nwere ike ịhazi ọkwa glucose ọbara nke ọma. Mmụba zuru ụwa ọnụ nke oke ibu na oke ibu emewo ka njikwa ibu bụrụ mkpa ụlọ ọgwụ ngwa ngwa. Ndị na-anabata GLP-1 nwere mmetụta na-ebelata ibu, na-eme ka ha bụrụ ebumnuche maka mbelata ibu. Tirzepatid enwetala nlebara anya n'ihi nsonaazụ mbelata ibu dị mma ya.

Kedu ihe bụ usoro nke Tirzepatid?

Ọrụ agonist receptor abụọ: 

Tirzepatid bụ dual glucagon-dị ka peptide-1 (GLP-1) na glucose dabere insulinotropic polypeptide (GIP) agonist receptor [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 na GIP bụ homonụ incretin na-emepụta n'ime eriri afọ, na-arụ ọrụ dị mkpa n'ịkwado glucose homeostasis. Tirzepatid na-arụ ọrụ synergistic site na ịgbalite GLP-1 na ndị na-anabata GIP n'otu oge, si otú a na-ahazi ọkwa glucose ọbara.

Usoro insulin na mmepụta glucagon: + 

Ọ na-abawanye njikọ insulin na nzuzo ma na-ebelata ntọhapụ glucagon n'ụzọ dabere na glucose. Mgbe ọkwa glucose ọbara na-ebili, Tirzepatid na-akpali sel β-pancreatic iji mepụta insulin, na-akwalite nnabata glucose na itinye n'ọrụ, si otú a na-ebelata ọkwa glucose ọbara; N'otu oge, ọ na-egbochi mkpụrụ ndụ α-pancreatic site na nzuzo glucagon, na-ebelata mmepụta glucose imeju, na-ebelata ọkwa glucose ọbara, na-achịkwa nke ọma ibu ọnụ na ọkwa glucose ọbara postprandial ^[1,3]..

Usoro ọrụ ndị ọzọ: 

Tirzepatid na-akwalitekwa satiety, nke nwere ike jikọta ya na ịgbalite ndị na-anabata GLP-1, na-eme ihe na sistemu ụjọ nke etiti, na-emetụta ụlọ ọrụ na-achịkwa agụụ, na-eduga ndị ọrịa iji belata oriri na-eri nri ma si otú a na-enyere aka na ọnwụ. Ọ na-egbu oge ịpụpụ afọ, na-agbatị oge nri na-adị n'ime afọ ma jiri nwayọọ nwayọọ na-abanye na eriri afọ, si otú a na-egbochi mmụba ngwa ngwa na ọkwa glucose ọbara ^[1]..

Ọgụgụ 1 Usoro ọrụ nke T irzepatide ^[6].

Kedu ihe bụ ngwa T irzepatide?

Ọgwụgwọ nke ụdị ọrịa shuga 2: 

A kwadoro Tirzepatid maka ọgwụgwọ ndị okenye nwere ụdị ọrịa shuga 2 dị ka ihe mgbakwunye nri na mmega ahụ. Nnwale SURPASS gosipụtara na Tirzepatid na-ebelata ọkwa hemoglobin A1c (HbA1c) nke ukwuu, yana mbelata sitere na -1.87% ruo -2.59% (-20 ruo -28 mmol/mol). Ọ na-egosipụtakwa njikwa glycemic dị elu ma e jiri ya tụnyere ụfọdụ agonists GLP-1 nnabata, dị ka semaglutide 1 mg na nnwale SUPRASS-2. Na mgbakwunye, ọ nwere ike ibelata ibu ahụ, yana oke ibu sitere na -6.2 ruo -12.9 kg na ọmụmụ ụlọ ọgwụ, nke dị oke mkpa maka ndị ọrịa nwere ụdị ọrịa shuga 2 nke na-enwekarị oke ibu ma ọ bụ oke ibu ^[1,4]..

Ọgwụgwọ oke ibu: 

Ebe ọ bụ na Tirzepatid na-akwalite satiety, na-ebelata iri nri, ma na-akwalite ibu ibu, ọ nwere uru ọgwụgwọ maka ndị ọrịa nwere oke ibu. Nnyocha na-egosi na ọ nwere ike belata ibu site na 20%, melite ọnọdụ metabolic nke ndị ọrịa, ma jee ozi dị ka nhọrọ ọgwụgwọ ọhụrụ maka oke ibu, na-enyere ndị ọrịa buru ibu aka ịkwụsị ibu ma belata ihe ize ndụ nke ọrịa dị iche iche metụtara oke ibu ^[1,2]..

Mbelata ihe ize ndụ nke ọrịa obi: 

Ndị ọrịa nwere ụdị ọrịa shuga 2 na-echekarị ihe ize ndụ dị ukwuu nke ọrịa obi. Na mgbakwunye na iwetulata shuga na ibu ọbara, Tirzepatid nwere mmetụta dị mma na ihe ngosi metụtara obi, gụnyere ibelata ọbara mgbali, mbelata mkpokọta abụba visceral, na ibelata ọkwa triglyceride na-ekesa, si otú a na-enyere aka belata ihe ize ndụ nke ọrịa obi ma melite nsonaazụ obi ndị ọrịa ^[4]..

Ọgwụgwọ enwere ike maka steatohepatitis na-abụghị mmanya (NASH): 

Tirzepatid nwere mmetụta ọgwụgwọ na NASH. Site na imeziwanye uche insulin na ịhazi glucose na metabolism lipid, ọ nwere ike belata steatosis imeju na mbufụt, na-enye ntụziaka ọhụrụ maka ọgwụgwọ NASH ^[5].

Mmechi

Dị ka GIP/GLP-1 dual agonist receptor, Tirzepatid egosila mmetụta dị ukwuu na ọgwụgwọ ọrịa shuga na nsogbu metabolic. Site n'ịhazi insulin na glucagon secretion, na-egbu oge ịpụsị afọ, na ime ka satiety dịkwuo elu, ọ na-ebelata ọkwa hemoglobin A1c nke ọma ma na-ebelata ibu onye ọrịa. Na mgbakwunye, ọgwụ ahụ na-eme ka ihe egwu dị egwu nke obi dị ka ọkwa lipid na ọbara mgbali elu ma gosipụta ịdị irè na steatohepatitis na-abụghị mmanya.

Banyere Onye dere ya

Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.

Onye ode akwụkwọ akụkọ sayensị

De Block C jikọtara ya na Mahadum Antwerp na ụlọ ọrụ ndị metụtara ya na Belgium, gụnyere Inflamed Ctr Excellence, University Hospital Antwerp (UZA na Univ Hosp Antwerp), na Infla Med Ctr Excellence. Nnyocha ya gbasara ọtụtụ ọzụzụ, dị ka Endocrinology & Metabolism, ebe ọ na-elekwasị anya na homonụ na ọrịa metabolic; Gastroenterology & Hepatology, ịchọpụta ọrịa digestive na imeju; General & Internal Medicine, na-agwa nchoputa na njikwa nke ọrịa ndị nkịtị; Nutrition & Dietetics, nyocha ihe oriri na mmetụta ahụike ya; na Urology & Nephrology, na-amụ banyere pathology na ụlọ ọgwụ omume nke urinary na akụrụ ọrịa. Ọ bụ ọkà mmụta nwere nnukwu onyinye n'ọtụtụ ngalaba ahụike. De Block C na-edepụtara na ntụaka nke ntụaka [4].

▎ Okwu ndị dị mkpa

[1] Wong E, Cope R, Dima L, et al. Tirzepatid: A Dual Glucose-based Insulinotropic Polypeptide na Glucagon-dị ka Peptide-1 Agonist maka njikwa nke ụdị 2 ọrịa shuga mellitus[J]. Akwụkwọ akụkọ American Therapeutics, 2023,30 (1): e26-e35.DOI: 10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, et al. Nkọwa na Tirzepatid, Ọgwụgwọ Abụọ Ezubere maka Ọrịa shuga na oke ibu [J]. Akwụkwọ akụkọ mba ụwa nke nyocha ọhụụ na uto, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, et al. Tirzepatid a akwụkwọ akụkọ mgbochi ọrịa shuga molecule na-ekpughere ọrụ abụọ [J]. Chọpụta ahụike ọha, 2024,21 (1): 75.DOI: 10.1186 / s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, et al. Tirzepatid maka ọgwụgwọ ndị okenye nwere ụdị ọrịa shuga 2: echiche endocrine [J]. Ọrịa shuga na-ebu oke ibu & Metabolism, 2023,25 (1): 3-17.DOI: 10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, et al. Ịgbanwe nlekọta ọrịa shuga: ikpughe ikike Tirzepatid na njikwa glycemic na karịa [J]. Nyocha ọkachamara nke Clinical Pharmacology, 2024,17 (3): 235-246.DOI: 10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, et al. Site na usoro glycocentric na onye ọrịa nwere ụdị ọrịa shuga mellitus nke 2 gaa na ọgwụgwọ mgbochi ọtụtụ akụkụ yana mbelata nsonaazụ neuro-nephro-cardiovascular.[M]//2023.DOI: 10.5772/intechopen.1002363.

Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.  

Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadobeghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.